Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.41 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19223073 | 1.00 | POLRMT (0.41) | POLRMTTRPM2ALDH1A1P2RY2P2RY6 | |
| SCHEMBL16519865 | 0.92 | POLRMT (0.38) | POLRMTSIRT2SIRT1 | |
| SCHEMBL15998230 | 0.88 | POLRMT (0.50) | POLRMTP2RX1P2RX3P2RX4 | |
| SCHEMBL20078675 | 0.88 | POLRMT (0.43) | POLRMTTRPM2P2RY2SIRT2SIRT1 | |
| SCHEMBL10120887 | 0.86 | POLRMT (0.53) | POLRMTP2RY2P2RX1P2RX3P2RX4 | |
| SCHEMBL17722662 | 0.86 | TMPRSS2 (0.45) | POLRMTTRPM2P2RY2P2RY6P2RY14 | |
| SCHEMBL20878443 | 0.86 | TMPRSS2 (0.45) | POLRMTTRPM2P2RY2P2RY6P2RY14 | |
| SCHEMBL21342881 | 0.86 | POLRMT (0.41) | POLRMTTRPM2P2RY2P2RY6P2RY14 | |
| SCHEMBL23960379 | 0.86 | POLRMT (0.41) | POLRMTTRPM2P2RY2P2RY6P2RY14 | |
| SCHEMBL22355504 | 0.85 | POLRMT (0.38) | POLRMTTRPM2ALDH1A1P2RY2P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11266666-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | POLRMT 104/4885TRPM2 1506/4885ALDH1A1 1121/4885 |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | POLRMT 104/4885TRPM2 1506/4885ALDH1A1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.